GlassScriptPhysician profile
Gregory Diamonti
NPI 1407810609
$3,123.47
in general payments reported to CMS, 2019-2025
21 companies · $743 in 2025
The $743 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.57 · 2020: $125 · 2022: $440 · 2023: $1,142 · 2024: $583 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,074.03 | 2019-2025 | Creon, Skyrizi, Rinvoq |
| Genzyme Corporation | $499.56 | 2022-2025 | |
| Janssen Biotech, INC. | $293.25 | 2023-2025 | Stelara, Tremfya, Remicade |
| Ardelyx, INC. | $199.84 | 2022-2023 | Ibsrela |
| Lilly USA, LLC | $187.87 | 2024-2025 | Omvoh |
| Celgene Corporation | $140.65 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $118.09 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $113.19 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $88.34 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $83.48 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $65.91 | 2023-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $37.24 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.24 | 2023-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $30.64 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.23 | 2024 | Eohilia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.47 | 2025 | |
| Braintree Laboratories, INC. | $24.24 | 2020 | |
| Olympus America INC. | $23.84 | 2023 | Endoclot Phs |
| Ironwood Pharmaceuticals, INC | $22.05 | 2023 | Linzess |
| Amgen INC. | $18.78 | 2025 | Uplizna |
| Ultragenyx Pharmaceutical INC. | $17.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Diamonti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.